Rx Head-To-Head Studies Require Careful Prioritization, NIH Says

NIH's role in head-to-head studies of pharmaceuticals must recognize the "limits" on the value of large comparative trials, National Institutes of Health Director Elias Zerhouni told Sen. Hillary Clinton (D-N.Y.) during an Oct. 2 hearing